Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study of the Effectiveness of Moderna COVID-19 Vaccine
- Conditions
- SARS-CoV-2COVID-19
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 927004
- Registration Number
- NCT05933304
- Locations
- πΊπΈ
Kaiser Permanente Southern California, Pasadena, California, United States
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Biological: mRNA-2736
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- ModernaTX, Inc.
- Registration Number
- NCT05918250
- Locations
- πΊπΈ
UAB Hospital, Birmingham, Alabama, United States
πΊπΈUniversity of Miami Health System, Miami, Florida, United States
πΊπΈWashington University Medical Center, Saint Louis, Missouri, United States
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
- Conditions
- SARS-CoV-2
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8844
- Registration Number
- NCT05894525
- Locations
- π―π΅
CMIC Co. Ltd.,, Tokyo, Japan
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
- Conditions
- SARS-CoV-2
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 13309
- Registration Number
- NCT05894499
- Locations
- π―π΅
CMIC Co., Ltd., Tokyo, Japan
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
- Conditions
- SARS-CoV-2
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 13680
- Registration Number
- NCT05894590
- Locations
- π―π΅
CMIC Co., Ltd, Tokyo, Japan
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05868382
- Locations
- πΊπΈ
CenExel RCA, Hollywood, Florida, United States
πΊπΈSuncoast Research Group, Miami, Florida, United States
πΊπΈJohnson County Clin-Trials, Lenexa, Kansas, United States
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- Biological: mRNA-1189Biological: mRNA-1195.1Biological: mRNA-1195.2Biological: Placebo
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 474
- Registration Number
- NCT05831111
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈNoble Clinical Research, Tucson, Arizona, United States
πΊπΈWest Coast Research, Dublin, California, United States
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
- Conditions
- InfluenzaSARS-CoV-2
- Interventions
- Biological: Investigational COVID-19 Vaccine 1Biological: COVID-19 Vaccine 1Biological: Influenza Vaccine 2Biological: Investigational Influenza Vaccine 1Biological: Influenza Vaccine 1Biological: Investigational Influenza Vaccine 2Biological: COVID-19 Vaccine 2Biological: Investigational COVID-19 Vaccine 2
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1763
- Registration Number
- NCT05827926
- Locations
- πΊπΈ
Chandler Clinical Trials, Chandler, Arizona, United States
πΊπΈBenchmark Research, San Angelo, Texas, United States
πΊπΈMarvel Clinical Research, Huntington Beach, California, United States
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
- Conditions
- Seasonal Influenza
- Interventions
- Biological: Licensed Quadrivalent Inactivated Seasonal Influenza VaccineBiological: mRNA-1010
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8422
- Registration Number
- NCT05827978
- Locations
- πΊπΈ
Pinnacle Research Group, Anniston, Alabama, United States
πΊπΈNorth Alabama Research Center LLC, Athens, Alabama, United States
πΊπΈCullman Research Center, Cullman, Alabama, United States
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
- Conditions
- Seasonal Influenza
- Interventions
- Biological: mRNA-1010.2Biological: mRNA-1010.3
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 698
- Registration Number
- NCT05827068
- Locations
- πΊπΈ
Long Beach Research Institute, Lakewood, California, United States
πΊπΈLong Beach Clinical Trials, Long Beach, California, United States
πΊπΈTekton Research, Moore, Oklahoma, United States